



## Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis

Prasun J Mishra

**To cite this article:** Prasun J Mishra (2014) Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis, Expert Review of Molecular Diagnostics, 14:8, 917-919, DOI: [10.1586/14737159.2014.971761](https://doi.org/10.1586/14737159.2014.971761)

**To link to this article:** <https://doi.org/10.1586/14737159.2014.971761>



Published online: 18 Oct 2014.



Submit your article to this journal [↗](#)



Article views: 1313



View related articles [↗](#)



View Crossmark data [↗](#)



Citing articles: 3 View citing articles [↗](#)

# Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis

Expert Rev. Mol. Diagn. 14(8), 917–919 (2014)



**Prasun J Mishra**

US Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Laboratory of Cancer Biology and Genetics, Bethesda, MD 20892, USA  
Tel.: +1 301 451 8522  
Fax: +1 301 480 4662  
mishrapj@mail.nih.gov

Developing more precise diagnostics approaches to predict cancer progression and prognosis is the key to precision medicine. Overwhelming evidence now suggests that small non-coding RNAs such as miRNAs can be useful tools as biomarkers for molecular diagnostics. miRNAs can serve as biomarkers in a variety of diseases, such as neurological disorders, cardiovascular disease, Type II diabetes, cancer and so on. miRNAs can not only be utilized for monitoring treatment but also for patient stratification and hence are promising predictive biomarkers in cancer progression and prognosis, as well as in predicting drug response. This article focuses on some of the recent findings in the field of miRNA biomarkers and discusses its implications for cancer diagnostics and precision medicine.

Small non-coding RNAs such as miRNAs are emerging as a new class of biomarkers. The cancer research field has been at the forefront of understanding miRNA biology and establishing miRNA as biomarkers for over a decade now [1]. This has been made possible not only by the availability of tumor tissue samples in the clinic but also recent advancements in the field of miRNA detection and sequencing technologies. miRNAs are now well established as regulators of tumorigenesis. In cancer, miRNA expression varies across different stages of tumor progression and its levels are altered (overexpressed/under-represented) during malignancy [1,2]. Over-expressed miRNAs in cancer may act like oncogenes by downregulating tumor suppressor genes. The opposite is also true; down-modulated tumor suppressor-like miRNAs result in upregulation of oncogenes, thereby functioning as tumor suppressors. Hence, in a malignant tumor, the oncogenic miRNAs are upregulated and tumor suppressor miRNAs are downregulated, which can be exploited as a biomarker. miRNAs are also tissue specific and may be unique identifiers of tumor type and origin [3]. An increasing number of miRNAs have now been identified and utilized as prognostic miRNAs to predict drug response.

Circulating miRNAs in bodily fluids, such as plasma, blood and urine, are promising candidates as noninvasive biomarkers for cancer. Circulating miRNAs are secreted by cancer cells in the surrounding tumor microenvironment in microvesicles or exosomes. Circulating miRNA signatures have been identified as being associated with a variety of cancer types, such as ovarian cancer [4], gastric cancer [5], breast cancer [6], multiple myeloma [7], lung squamous cell carcinoma [8], brain cancer [9], prostate cancer [10] and Hodgkin's lymphoma [11]. For example, it has been shown that exosomal miRNAs, such as miR-21 and miR-29a, can be engulfed by the immune cells from surrounding cancer cells and can bind to Toll-like receptor 8 in the immune cells to induce secretion of interleukin-6 and TNF- $\alpha$ , which is associated with tumor growth [12,13]. Recently, it has been reported that Let-7 family members are secreted into the extracellular space via exosomes [5]. Furthermore, high levels of circulating miR-200 family members have been reported in epithelial ovarian cancer [14] as well as gastric cancer [15]. Moreover, the circulating miRNAs present a promising opportunity for cancer diagnostics and precision medicine.

EXPERT  
REVIEWS

**KEYWORDS:** biomarker • circulating microRNAs • diagnostics • miRNA • miRNA polymorphisms • microvesicles or exosomes • pharmacogenomics • precision medicine • prognosis • variants

Tissue slide-based assays to guide treatment options are routine in clinical pathological laboratories. Recently, tissue slide-based approaches have been developed for miRNA detection and their efficacy has been tested in pancreatic cancer. Changes in the levels of miRNAs between normal and tumor tissues in pancreatic cancer have been documented [16]. The pancreatic tissue is very diverse and only some pancreatic cells are prone to developing cancer. Hence, it is important to know the miRNA changes in the cancer-prone cells and not the normal cells. A tissue slide-based staining assay in a chemiluminescence immunoassay-certified environment was developed utilizing *in situ* hybridization to identify specific miRNAs' alterations (examples are miR-21 and miR-34a) in the pancreas of mice that develop pancreatic cancer. The technique could be potentially useful in measuring miRNA levels and their location within cellular compartments in pancreatic tissue and have potential diagnostic applications [17].

miRNAs have been identified as predictive biomarkers for many cancer types [1]. For example, in colorectal cancer, miR-215 was identified as suppressing the expression of both thymidylate synthase and dihydrofolate reductase and its expression was associated with colorectal cancer patient survival [18]. Another miRNA, miR-140, was found to modulate chemosensitivity by suppressing histone deacetylase 4 expression, and the levels of both miR-140 and miR-215 were elevated in colon cancer stem cells [19]. To predict metastasis and prognosis in clear cell renal cell carcinoma a 4-miRNA signature was identified [20,21]. Of interest, the signature can be validated on a formalin-fixed paraffin-embedded tissue and reverse transcription-polymerase chain reaction-based assay and serve as a predictive biomarker for clear cell renal cell carcinoma. Taken together, these few examples demonstrate that miRNAs can be utilized in predicting patients' prognosis and survival in the clinic.

Variants or polymorphisms in miRNA can be also utilized as tools for prognosis and progression of diseases and drug responses. These genetic variations are emerging as powerful tools to study biology of many diseases including cancer [22,23]. miRNA variants or polymorphisms (miR-polymorphisms) can be defined as polymorphisms (chromosomal changes, single nucleotide polymorphisms, mutations, alterations, variations and epigenetic defects) that may functionally interfere with miRNA-mediated regulation of cellular functions. These variations can be present not only in the miRNA target gene but also in pri-, pre-, mature-miRNA

sequences, in the genes involved in miRNA biogenesis and in miRNA *cis*-regulatory elements (such as a promoter) [24]. Presumably, a polymorphism in a mature miRNA sequence may affect the expression of a number of genes and have deleterious effects on cell function. On the other hand, a variant in the target site of a miRNA may be more gene and/or pathway specific [24]. The discovery of the role of miRNA in drug resistance and miRNA variations to predict drug response has led to the development of a new field in biomedical science called miRNA pharmacogenomics, a study of the miRNAs and miRNA variants affecting expressions of drug target genes, to predict drug behavior and to improve drug efficacy. Taken together, the data suggest that detection of miRNA-polymorphisms can potentially improve diagnosis, treatment and prognosis in patients and has profound implications in the fields of pharmacogenomics and precision medicine [25].

In conclusion, the role of miRNA in tumorigenesis is now well established [1]. miRNAs can be exploited as novel biomarkers for the cancer diagnosis and prognosis and to predict drug response. Detection of circulating miRNAs (e.g., from blood, urine and so on) may present a noninvasive tool for cancer diagnostics. Technologies utilizing tissue slide-based miRNA detection methods may be useful in finding tissue specific localization of miRNAs. Finally, miRNA variants can be utilized to predict diagnosis, treatment and prognosis in cancer patients. Taken together, these new findings indicate that levels of miRNA in cancer can be utilized in developing a personalized anticancer therapy.

### Acknowledgements

*This editorial discusses recent advancements in miRNA cancer diagnostics field presented at the 2014 microRNA as Biomarkers and Diagnostics conference, Boston, MA, USA. This study was supported by the Intramural Research Program of the Center of Cancer Research, NCI, NIH, and in part by NCI Director's Innovation Awards in 2009 and 2011 (to PJ Mishra). This is a US government study and is in the public domain of United States of America.*

### Financial & competing interests disclosure

*The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.*

*No writing assistance was utilized in the production of this manuscript.*

### References

1. Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nat Rev Cancer* 2006;6(11):857-66
2. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proc Natl Acad Sci USA* 2002;99(24): 15524-9
3. Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in cancer. *J Clin Invest* 2009;119(8):2119-23
4. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol Oncol* 2008;110(1):13-21
5. Ohshima K, Inoue K, Fujiwara A, et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. *PLoS One* 2010;5(10):e13247
6. Sieuwerts AM, Mostert B, Bolt-de Vries J, et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. *Clin Cancer Res* 2011;17(11): 3600-18
7. Jones CI, Zabolotskaya MV, King AJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. *Br J Cancer* 2012;107(12): 1987-96

8. Aushev VN, Zborovskaya IB, Laktionov KK, et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. *PLoS One* 2013;8(10):e78649
9. Camacho L, Guerrero P, Marchetti D. MicroRNA and protein profiling of brain metastasis competent cell-derived exosomes. *PLoS One* 2013;8(9):e73790
10. Cheng HH, Mitchell PS, Kroh EM, et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. *PLoS One* 2013;8(7):e69239
11. Jones K, Nourse JP, Keane C, et al. Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. *Clin Cancer Res* 2014;20(1):253-64
12. Challagundla KB, Fanini F, Vannini I, et al. microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics. *Expert Rev Mol Diagn* 2014;14(5):565-74
13. Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. *Proc Natl Acad Sci USA* 2012;109(31):E2110-16
14. Kan CW, Hahn MA, Gard GB, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. *BMC Cancer* 2012;12:627
15. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. *J Transl Med* 2012;10:186
16. Sempere LF. Recent advances in miRNA-based diagnostic applications. *Expert Rev Mol Diagn* 2012;12(6):557-9
17. Sempere LF, Korc M. A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. *Methods Mol Biol* 2013;980:43-59
18. Song B, Wang Y, Titmus MA, et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. *Mol Cancer* 2010;9:96
19. Karaayvaz M, Pal T, Song B, et al. Prognostic significance of miR-215 in colon cancer. *Clin Colorectal Cancer* 2011;10(4):340-7
20. Weng L, Wu X, Gao H, et al. MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. *J Pathol* 2010;222(1):41-51
21. Wu X, Weng L, Li X, et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. *PLoS One* 2012;7(5):e35661
22. Mishra PJ, Humeniuk R, Mishra PJ, et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. *Proc Natl Acad Sci USA* 2007;104(33):13513-8
23. Mishra PJ, Song B, Mishra PJ, et al. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. *PLoS One* 2009;4(12):e8445
24. Mishra PJ. The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins. *Pharmacogenomics* 2012;13(12):1321-4
25. Mishra PJ. MicroRNA polymorphisms: a giant leap towards personalized medicine. *Per Med* 2009;6(2):119-25